Biocon inks licensing pact with US-based Quark Pharma

Last Updated: Wednesday, December 18, 2013, 14:40

Biotechnology major Biocon on Wednesday said it has inked a pact with Quark Pharmaceuticals, Inc to develop a range of siRNA (small interfering RNA) based novel therapeutics.

Indian biotech aiming to be $100 bn sector by 2025: Shaw

Last Updated: Saturday, November 16, 2013, 19:37

If farmers are to become prosperous you need technology, she added.

Biocon chief seeks spl session to discuss crime against women

Last Updated: Friday, August 30, 2013, 16:16

Biocon Limited chief and Bangalore Political Action Committee president Kiran Mazumdar Shaw today asked Chief Minister Siddaramaiah to convene a special session of the Legislature to discuss crime against women.

Biocon launches biological drug to combat psoriasis

Last Updated: Saturday, August 10, 2013, 20:14

Bangalore-headquartered biotechnology company Biocon Saturday announced the launch of a biological drug researched, developed and manufactured in the country to treat chronic plaque psoriasis and said it is in discussions to finalise a global partner to take it worldwide.

Biocon Q1 net up 19% at Rs 93.50 cr

Last Updated: Friday, July 26, 2013, 10:14

Consolidated total income of the company also rose to Rs 700.69 crore for the April-June, 2013 quarter as against Rs 576.68 crore for the year ago period.

Biocon to replace Indian Hotels from NSE's Nifty Midcap 50

Last Updated: Monday, July 22, 2013, 21:03

Biotech company Biocon will be included in the National Stock Exchange's Nifty Midcap 50 index, replacing the Tata group hospitality major Indian Hotels Company from next month.

Ranbaxy issue a wake up call for Indian pharma industry: Shaw

Last Updated: Sunday, June 9, 2013, 11:13

The USD 500 million fine on Ranbaxy by US authorities after it pleaded guilty to "felony charges" for violating drug manufacturing norms is "a wake up call" for Indian pharmaceutical industry, according to Biocon Chairman and Manging Director Kiran Mazumdar-Shaw.

Biocon seeking partners to develop, market psoriasis drug

Last Updated: Wednesday, June 5, 2013, 18:15

Biotechnology major Biocon Wednesday said it is looking for partners to develop and market its novel biologic drug Itolizumab, branded as 'Alzumab', to be used for the treatment of chronic plaque ps oriasis worldwide.

Biocon to launch psoriasis drug novel biologic in July

Last Updated: Sunday, April 28, 2013, 18:08

"We plan to launch Alzumab (Itolizumab) in July this year in the country. It is a novel, first-in-class biologic for the treatment of psoriasis," Biocon Chairman and Managing Director Kiran Mazumdar-Shaw said in an interview.

Biocon Q4 consolidated net up over two-fold to Rs 248.61 crore

Last Updated: Friday, April 26, 2013, 13:28

Consolidated net sales of the company, however, rose to Rs 630.12 crore for quarter ended March 31, 2013 from Rs 589.22 crore for the same period a year ago.

Biocon inks pact with Mylan to develop three insulin products

Last Updated: Thursday, February 14, 2013, 13:39

The Bangalore-based firm has entered into a definitive agreement with Mylan for an exclusive strategic collaboration for the global development and commercialisation of generic versions of its three insulin analog products, Biocon Ltd said in a statement.

Policies in isolation stalling eco growth: Mazumdar-Shaw

Last Updated: Tuesday, January 29, 2013, 17:23

India's economic growth is "stalled" because government policies are framed in isolation and ministries are not working in concert, Kiran Mazumdar- Shaw, Chairman and Managing Director of biotech major Biocon Ltd, said Tuesday.